HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Angusti, T. Articles by Favero, A. Search for Related Content PubMed PubMed Citation Articles by Angusti, T. Articles by Favero, A.

Thyroid Cancer Prevalence After Radioiodine Treatment of Hyperthyroidism

Unità Operativa Autonoma di Medicina Nucleare, Dipartimento di Oncologia, Ospedale Mauriziano Umberto I Torino, Torino, Italy

Correspondence: For correspondence or reprints contact: Alessandro Favero, MD, Department of Nuclear Medicine, Mauriziano Hospital, Corso Turati 46, Turin 10128, Italy.

ABSTRACT

The definitive treatment of hyperthyroidism in Europe is quite different from that in the United States. In Europe, the surgical approach is often preferred and considered safer than radioiodine treatment. European doctors usually prefer to surgically remove the thyroid and perform a pathologic examination of it. They consider it to be an essential diagnostic tool to identify possible diseases that might be associated with hyperthyroidism and even to detect the rare thyroid tumors that might be associated with thyroid hyperfunction. The aim of this study was to evaluate whether radioiodine therapy could be a risk factor for the misdiagnosis of thyroid cancer. Methods: We performed a retrospective revision of data we collected from 6647 patients (1171 [17.5%] men, 5476 [82.5%] women), all of whom underwent ¹³¹I therapy for hyperthyroidism from 1970 to 1997. Of the whole group, 6.5% were younger than 40 y, 33.5% were 40–60 y old, and 60% were older than 60 y. Moreover, 5061 (76%) patients had either an autonomously functioning node or a toxic multinodular goiter. The other 1586 (24%) patients had Graves' disease. Results: After treatment, thyroid cancer was discovered in 10 (0.15%) patients, none of whom belonged to the group of patients with Graves' disease. Five of these patients were treated during a period from 1970 to 1980, when sonography was not routinely available. The incidence of thyroid cancer in the series of radioiodine-treated patients (150/100,000 over a 27-y period) was not significantly different from its incidence in the general population. The expected rate is 124.88 per 100,000 over a 27-y period. Conclusion: An accurate preliminary evaluation (clinical examination, sonography, and cytologic evaluation of fine-needle aspiration) is fundamental for a proper choice between radioiodine and surgical therapy.

Key Words: hyperthyroidism • radioiodine treatment • thyroid cancer

This article has been cited by other articles:

				W. Muhammad, S. Faaruq, A. Hussain, M. B. Kakakhail, S. Fatmi, and Matiullah Quantitative analysis of the factors responsible for over or under dose of 131I therapy patients of hyperthyroidism Radiat Prot Dosimetry, January 1, 2008; 128(1): 90 - 97. [Abstract] [Full Text] [PDF]

				L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek Management of Simple Nodular Goiter: Current Status and Future Perspectives Endocr. Rev., February 1, 2003; 24(1): 102 - 132. [Abstract] [Full Text] [PDF]

				A. Allahabadia, J. Daykin, M. C. Sheppard, S. C. L. Gough, and J. A. Franklyn Radioiodine Treatment of Hyperthyroidism--Prognostic Factors for Outcome J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3611 - 3617. [Abstract] [Full Text] [PDF]